Ruxolitinib
Ruxolitinib, sold under the brand names Jakafi and Jakavi, is a medication for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, polycythemia vera (PCV) when there has been an inadequate response to or intolerance of hydroxyurea, and steroid-refractory acute graft-versus-host disease. It was developed and marketed by Incyte Corp in the US under the brand name Jakafi, and by Novartis elsewhere in the world, under the brand name Jakavi.
Q12140
medication
Concept
Q1752571
myelofibrosis
Concept
Q948318
polycythemia vera
Concept
Q212272
hydroxyurea
Concept
Q6015591
Incyte Corp
ORG
Q507154
Novartis
ORG
Q7383611
Ruxolitinib
Concept
instance of
medical condition treated
medical condition treated
instance of